000128877 001__ 128877
000128877 005__ 20240228143354.0
000128877 0247_ $$2doi$$a10.1038/bcj.2016.46
000128877 0247_ $$2pmid$$apmid:27471865
000128877 0247_ $$2pmc$$apmc:PMC5030374
000128877 0247_ $$2altmetric$$aaltmetric:10130594
000128877 037__ $$aDKFZ-2017-04890
000128877 041__ $$aeng
000128877 082__ $$a610
000128877 1001_ $$0P:(DE-He78)ce3cd0df5fbbdf8768f6f1cd543bce72$$aKayser, Sabine$$b0$$eFirst author$$udkfz
000128877 245__ $$aPretransplant NPM1 MRD levels predict outcome after allogeneic hematopoietic stem cell transplantation in patients with acute myeloid leukemia.
000128877 260__ $$aLondon [u.a.]$$bNature Publishing Group$$c2016
000128877 3367_ $$2DRIVER$$aarticle
000128877 3367_ $$2DataCite$$aOutput Types/Journal article
000128877 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1524467175_17417
000128877 3367_ $$2BibTeX$$aARTICLE
000128877 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000128877 3367_ $$00$$2EndNote$$aJournal Article
000128877 520__ $$aThe objective was to evaluate the prognostic impact of pre-transplant minimal residual disease (MRD) as determined by real-time quantitative polymerase chain reaction in 67 adult NPM1-mutated acute myeloid leukemia patients receiving allogeneic hematopoietic stem cell transplantation (HSCT). Twenty-eight of the 67 patients had a FLT3-ITD (42%). Median age at transplantation was 54.7 years, median follow-up for survival from time of allografting was 4.9 years. At transplantation, 31 patients were in first, 20 in second complete remission (CR) and 16 had refractory disease (RD). Pre-transplant NPM1 MRD levels were measured in 39 CR patients. Overall survival (OS) for patients transplanted in CR was significantly longer as compared to patients with RD (P=0.004), irrespective of whether the patients were transplanted in first or second CR (P=0.74). There was a highly significant difference in OS after allogeneic HSCT between pre-transplant MRD-positive and MRD-negative patients (estimated 5-year OS rates of 40 vs 89%; P=0.007). Multivariable analyses on time to relapse and OS revealed pre-transplant NPM1 MRD levels >1% as an independent prognostic factor for poor survival after allogeneic HSCT, whereas FLT3-ITD had no impact. Notably, outcome of patients with pre-transplant NPM1 MRD positivity >1% was as poor as that of patients transplanted with RD.
000128877 536__ $$0G:(DE-HGF)POF3-317$$a317 - Translational cancer research (POF3-317)$$cPOF3-317$$fPOF III$$x0
000128877 588__ $$aDataset connected to CrossRef, PubMed,
000128877 7001_ $$0P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aBenner, A.$$b1$$udkfz
000128877 7001_ $$aThiede, C.$$b2
000128877 7001_ $$aMartens, U.$$b3
000128877 7001_ $$aHuber, J.$$b4
000128877 7001_ $$aStadtherr, P.$$b5
000128877 7001_ $$aJanssen, J. W. G.$$b6
000128877 7001_ $$aRöllig, C.$$b7
000128877 7001_ $$aUppenkamp, M. J.$$b8
000128877 7001_ $$0P:(DE-He78)c741dc7f974390ad4310349f29aac40b$$aBochtler, T.$$b9$$udkfz
000128877 7001_ $$aHegenbart, U.$$b10
000128877 7001_ $$aEhninger, G.$$b11
000128877 7001_ $$aHo, A. D.$$b12
000128877 7001_ $$aDreger, P.$$b13
000128877 7001_ $$0P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aKrämer, Alwin$$b14$$eLast author$$udkfz
000128877 773__ $$0PERI:(DE-600)2600560-8$$a10.1038/bcj.2016.46$$gVol. 6, no. 7, p. e449 -$$n7$$pe449 -$$tBlood cancer journal$$v6$$x2044-5385$$y2016
000128877 909CO $$ooai:inrepo02.dkfz.de:128877$$pVDB
000128877 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)ce3cd0df5fbbdf8768f6f1cd543bce72$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000128877 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)e15dfa1260625c69d6690a197392a994$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000128877 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c741dc7f974390ad4310349f29aac40b$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000128877 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)493c5fbf69f1b20df6f048712f3ad4a0$$aDeutsches Krebsforschungszentrum$$b14$$kDKFZ
000128877 9131_ $$0G:(DE-HGF)POF3-317$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vTranslational cancer research$$x0
000128877 9141_ $$y2016
000128877 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bBLOOD CANCER J : 2015
000128877 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000128877 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000128877 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000128877 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal
000128877 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ
000128877 915__ $$0LIC:(DE-HGF)CCBYNV$$2V:(DE-HGF)$$aCreative Commons Attribution CC BY (No Version)$$bDOAJ
000128877 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bThomson Reuters Master Journal List
000128877 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000128877 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000128877 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine
000128877 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000128877 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000128877 9201_ $$0I:(DE-He78)G330-20160331$$kG330$$lKKE Molekulare Hämatologie/Onkologie$$x0
000128877 9201_ $$0I:(DE-He78)C060-20160331$$kC060$$lBiostatistik$$x1
000128877 980__ $$ajournal
000128877 980__ $$aVDB
000128877 980__ $$aI:(DE-He78)G330-20160331
000128877 980__ $$aI:(DE-He78)C060-20160331
000128877 980__ $$aUNRESTRICTED